These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 29602036

  • 1. Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
    Zhang L, Zhao J, Zhang B, Lu T, Chen Y.
    Eur J Med Chem; 2018 Apr 25; 150():809-816. PubMed ID: 29602036
    [Abstract] [Full Text] [Related]

  • 2. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA, Sakr H, Ayyad RRA, El-Adl K, Ali MM, Khedr F.
    Anticancer Agents Med Chem; 2018 Apr 25; 18(8):1184-1196. PubMed ID: 29651967
    [Abstract] [Full Text] [Related]

  • 3. Transforming Type II to Type I c-Met kinase inhibitors via combined scaffold hopping and structure-guided synthesis of new series of 1,3,4-thiadiazolo[2,3-c]-1,2,4-triazin-4-one derivatives.
    El-Wakil MH, Teleb M.
    Bioorg Chem; 2021 Nov 25; 116():105304. PubMed ID: 34534756
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
    Nan X, Li HJ, Fang SB, Li QY, Wu YC.
    Eur J Med Chem; 2020 May 01; 193():112241. PubMed ID: 32200199
    [Abstract] [Full Text] [Related]

  • 6. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
    Zhang D, Ai J, Liang Z, Li C, Peng X, Ji Y, Jiang H, Geng M, Luo C, Liu H.
    Bioorg Med Chem; 2012 Sep 01; 20(17):5169-80. PubMed ID: 22863529
    [Abstract] [Full Text] [Related]

  • 7. Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as c-Met kinase inhibitors.
    Liu J, Nie M, Wang Y, Hu J, Zhang F, Gao Y, Liu Y, Gong P.
    Eur J Med Chem; 2016 Nov 10; 123():431-446. PubMed ID: 27490023
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X, Bao G, Wang L, Cheng M, Zhao M, Zhao S, Zhou H, Gong P.
    Bioorg Med Chem; 2016 Mar 15; 24(6):1331-45. PubMed ID: 26897090
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
    Wang W, Xu S, Duan Y, Liu X, Li X, Wang C, Zhao B, Zheng P, Zhu W.
    Eur J Med Chem; 2018 Feb 10; 145():315-327. PubMed ID: 29331754
    [Abstract] [Full Text] [Related]

  • 10. Triazolopyridazine derivatives: Synthesis, cytotoxic evaluation, c-Met kinase activity and molecular docking.
    Ahmed EM, Khalil NA, Taher AT, Refaey RH, Nissan YM.
    Bioorg Chem; 2019 Nov 10; 92():103272. PubMed ID: 31539742
    [Abstract] [Full Text] [Related]

  • 11. Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
    Tang Q, Wang L, Tu Y, Zhu W, Luo R, Tu Q, Wang P, Wu C, Gong P, Zheng P.
    Bioorg Med Chem Lett; 2016 Apr 01; 26(7):1680-4. PubMed ID: 26923692
    [Abstract] [Full Text] [Related]

  • 12. Discovery of a novel 6,7-disubstituted-4-(2-fluorophenoxy)quinolines bearing 1,2,3-triazole-4-carboxamide moiety as potent c-Met kinase inhibitors.
    Liu M, Hou Y, Yin W, Zhou S, Qian P, Guo Z, Xu L, Zhao Y.
    Eur J Med Chem; 2016 Aug 25; 119():96-108. PubMed ID: 27155466
    [Abstract] [Full Text] [Related]

  • 13. Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase.
    Liu Y, Jin S, Peng X, Lu D, Zeng L, Sun Y, Ai J, Geng M, Hu Y.
    Eur J Med Chem; 2016 Jan 27; 108():322-333. PubMed ID: 26698536
    [Abstract] [Full Text] [Related]

  • 14. O-linked triazolotriazines: potent and selective c-Met inhibitors.
    Chen F, Wang Y, Ai J, Zhan Z, Lv Y, Liang Z, Luo C, Mei D, Geng M, Duan W.
    ChemMedChem; 2012 Jul 27; 7(7):1276-85. PubMed ID: 22539497
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Design, synthesis and biological evaluation of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties as c-Met kinase inhibitors.
    Liu Z, Wang R, Guo R, Hu J, Li R, Zhao Y, Gong P.
    Bioorg Med Chem; 2014 Jul 15; 22(14):3642-53. PubMed ID: 24882675
    [Abstract] [Full Text] [Related]

  • 17. Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met.
    Ibrahim HA, Awadallah FM, Refaat HM, Amin KM.
    Bioorg Chem; 2018 Apr 15; 77():457-470. PubMed ID: 29453077
    [No Abstract] [Full Text] [Related]

  • 18. Synthesis of novel 6,7-dimethoxy-4-anilinoquinolines as potent c-Met inhibitors.
    Zhang QW, Ye ZD, Shen C, Tie HX, Wang L, Shi L.
    J Enzyme Inhib Med Chem; 2019 Dec 15; 34(1):124-133. PubMed ID: 30422010
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Design, microwave assisted synthesis, and molecular modeling study of some new 1,3,4-thiadiazole derivatives as potent anticancer agents and potential VEGFR-2 inhibitors.
    Atta-Allah SR, AboulMagd AM, Farag PS.
    Bioorg Chem; 2021 Jul 15; 112():104923. PubMed ID: 33932767
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.